A B S T R A C T 17 patients with chronic ventilatory failure (including 14 with chronic obstructive pulmonary disease) were studied to determine the causes of carbon dioxide retention and the chronic effect of medroxyprogesterone acetate on ventilatory drive and acid-base status. Carbon dioxide retention in patients with high mechanical loads occurred concomitantly with a higher than normal inspiratory effort (mouth occlusion pressure) and normal minute ventilation to carbon dioxide production ratio (VIE/Vco2); but with shortened inspiratory time (1.3±0.1 vs. 1.8±3 s), increased breathing frequency (17±1 vs. 14±1 breaths/ min), low tidal volume (0.57±0.03 vs. 0.88±0.04 L), and high dead space to tidal volume ratio (0.63±0.02 vs. 0.39±0.07). Using a randomized application of treatment and placebo conditions, it was shown that 4 wk ofmedroxyprogesterone acetate caused significant reductions in Paco2 (from 51 + 1 to 42±1 mm Hg) in 10 of 17 patients. This "correction" of Paco2 in these patients was associated with increases in mouth occlusion pressure (14%), tidal volume (11%), and alveolar ventilation (15%) compared to placebo, although inspiratory time remained shortened. Arterial and lumbar cerebrospinal fluid pH was alkaline compared to placebo in patients who "corrected" Paco2. No change was noted in lung mechanics or core temperature. Common prerequisites for correction of Paco2 with medroxyprogesterone acetate treatment were the ability to significantly lower Paco2 upon acute voluntary hyperventilation and to increase tidal volume rather than breathing frequency in response to the drug. We attribute chronic CO2 retention in these patients to alterations in respiratory cycle timing and to a neuromuscular inspiratory effort which is adequate for the level of tissue CO2
INTRODUCTION
Progesterone was first implicated as a ventilatory stimulant when Hasselbalch and Gammeltoft described hyperventilation and a decreased end-tidal Pco2 in women during pregnancy and during the luteal phase of the menstrual cycle (1, 2) . In normal males, progesterone administration produced sustained hyperventilation and decreased Paco2 (3) (4) (5) . Similarly, a synthetic progestin, medroxyprogesterone acetate (MPA),1 lowered the Paco2 5 mm Hg in normal subjects by a mechanism independent of arterial blood or cerebrospinal fluid (CSF) [H+] (6) .
Progestins have been used therapeutically in the obesity-hypoventilation syndrome and chronic mountain polycythemia, producing increased alveolar ventilation and lower Paco2 in most patients (7) (8) (9) . Efficacy of treatment in patients with chronic obstructive pulmonary disease (COPD) and chronic CO2 retention have been less consistent (10, 11) . Lyons described some emphysematous patients who benefited from progesterone, whereas other patients described subjective discomfort due to dyspnea despite improved arterial blood gases (12) . Therefore, although the therapeutic efficacy of progestins has been documented in the obesity-hypoventilation syndrome and chronic mountain polycythemia, its usefulness and predictaIAbbreviations used in this paper: A-a, alveolar-arterial; COPD, chronic obstructive pulmonary disease; CSF, cerebrospinal fluid; DLCOSB, single-breath diffusion capacity; dp/dt max, maximum slope of the inspiratory pressure curve; f, respiratory frequency; FEV,, forced expiratory volume in 1 s; MPA, medroxyprogesterone acetate; Po.,, mouth occlusion pressure at 100 ms; TI, inspiratory time; VA, alveolar ventilation; Vco2, CO2 production (liters per minute); VE, expired minute ventilation; VHV, voluntary hyperventilation; VT, tidal volume. bility of response in patients with moderate to severe COPD and CO2 retention has not been established.
CO2 retention in these patients has been attributed to both abnormal respiratory cycle timing (13) and decreased inspiratory "drive" or effort in response to increased mechanical load and abnormal ventilation/ perfusion relationships. Previous cross-sectional studies have not provided experimental documentation for these alternative explanations. By examnining such factors as respiratory cycle timing and inspiratory effort before and during MPA therapy, the present study attempts to characterize the ventilatory response to MPA and to use this response to experimentally assess alternative mechanisms of chronic CO2 retention. METHODS Studij population. 17 outpatients, age 42-68, with stable chronic CO2 retention were studied. Their mean weight was 94±15 kg with a range of 70-230 kg. 14 patients had moderate to severe COPD and 2 ofthese had lobectomies. In an attempt to use the MPA response to assess possible mechanisms of CO2 retention in diseases other than COPD, three patients without airway obstruction were studied. One subject had primary alveolar hypoventilation with normal body weight, pulmonary function, and nocturnal sleep record. Two subjects were massively obese (137 and 230 kg) without airway obstruction. Nocturnal sleep recording in one subject showed periodic breathing with occasional central apnea lasting less than 10 s. Although no formal sleep study was performed in the other patient, apnea was observed on several occasions when the subject appeared to fall asleep while breathing on the mouthpiece. Patient data were compared to those of five normal subjects with mean-+±SD of age and weight similar to the patients. Informed consent was obtained from both the patients and the normal subjects.
Only patients with stable CO2 retention and pulmonary function for the previous 6 mo were selected. Studies were not performed during exacerbation of symptoms. Patients Morris et al. (14) . Singlebreath diffusion capacity (DLCOSB) was measured using a modified technique of Ogilvie et al. (15) . Functional residual capacity was measured in a body plethysmograph using Boyle's law techniques. Resistance of the respiratory system was determined during inspiration (at 0.5 liters/s flow rate) and at end expiration by the forced oscillation technique at 4 and 10 Hz using an automated system for resistance of the respiratory system measurement similar to that described by Hyatt et al. (16) .
Arterial blood samples were obtained from an indwelling brachial or radial artery catheter. During each study period, four to six blood specimens were drawn over a 20-30-min period while the patient was supine, in a quiet laboratory, and breathing room air. The patient remained supine and breathed air through a mouthpiece attached to a two-way valve while continuous measurements were made of expired ventilation through a heated Fleisch No. 2 pneumotachograph with integration of the flow signal by an Electronics for Medicine pulmonary function plug-in integrator (Electronics for Medicine, Pleasantville, N. Y.) and breath-by-breath end-tidal Pco2 (LB2, Beckman Instruments Inc., Fullerton, Calif.) to insure steady-state conditions for blood sampling. Inspiratory and expiratory time (T, and TE) were obtained from the flow signal of the pneumotachograph. An arterial blood specimen was drawn over 1 min and analyzed at 37°C for pH, Paco2 and Pao2 with a Radiometer blood gas analyzer (Radiometer Co., Copenhagen, Denmark). Calibration of Pao2 and Paco2 electrodes were frequently validated using tonometered blood (17) . At the same time, mixed expired gas was obtained and analyzed for C02, 02, and N2 with a gas chromatograph (QuinTron Instrument Co., Inc., Milwaukee, Wis.). Dead space, 02 consumption, CO2 production, and respiratory exchange ratio were then calculated. This sequence of measurements was then repeated while the subject breathed mixtures of 30, 50, and 100% 02 for 5 min.
While the patient was breathing room air, 02, and C02, the mouth occlusion pressure and the maximal slope of the inspiratory pressure curve (dp/dt max) were obtained. A Statham PM5-E-0.2-350 pressure transducer (range, + 15 cm H20; Statham Instruments, Inc., Oxnard, Calif.) measured changes in mouth pressure during random occlusions obtained 0.1 s after the onset of the occluded inspiration (P0.,). Po.1 was expressed as the mean of 6-10 occlusions performed at least 30 s apart. The dp/dt max was obtained breath-by-breath and expressed as the mean of 25 breaths by electronically differentiating the inspiratory pressure signal measured at the mouth as described by Matthews and Howell (18) and by Skatrud et al. (6) .
Carbon dioxide response studies were performed using a rebreathing technique as described by Read (19) . Voluntary hyperventilation (VHV) maneuvers were performed in two different ways. First, the patient breathed as fast and deep as possible for 30 s with an arterial blood sample drawn between 15 and 30 s. After a rest, a slower but deeper maneuver was performed for 60 s with arterial blood drawn between 30 and 60 s. In both cases, the blood samples were obtained only after end-tidal Pco2 had achieved a relatively steady state.
Lumbar puncture was performed in seven patients during placebo and treatment periods and analyzed for MPA. The techniques for anaerobic sampling and acid-base analyses of lumbar spinal fluid have been described previously (17) .
MPA levels in plasma and CSF were determined by radioimmunoassay as previously described (6) .
Statistical differences between means were determined by combining analysis of variance for repeated measures over all four conditions (control vs. placebo I vs. placebo II vs. Reprodticilbilitiy a(1(1 placebo effect. We tested the reprodticibilitv of all ventilatory, arterial blood gas, and inspiratory effort meassuremiienits (durinig the resting, air-breathing state betwveen test sessions. No systematic dlifference was noted betweeni placel)bo sessionis for any of the measured variables incbltudinlg expirecl minuite ventilation (VE), alveolar ventilation (VA), tidal volume (VT), respiratory frequency (f), P0.1, dp/dt Imcax, pH, and(I Paco2 (P > 0.1). Random variability of (lifferences between imieani values for individual patients on two placebo sessionls was obtained by dlividing the standard error of the (liffereinces between paired measuremienits by the grand miiean11 and(I expressing as a percentage. Random variability was as follows: (a) VE, VA, VT, and f (+2-4%); (b) Po., and( dIp/dt max (±8-9%); and(c (c) pH and Paco2 (+ 1%). RESULTS CO2 retahiners ts. normals. C02 retainers were comnpared to normiials to determiiine factors associated with CO2 retenitioni (Tables I and II) . Alveolar ventilation was low in spite of a normiial minute ventilation to CO2 prodluctioni ratio (VE/VCO2 = 46+3 vs. 47±3 in normals). Indices of respiratory ceniter drive (Po.1 and dp/dt Imlax) were 76 anid 42% greater than normal Correctors raised Pao2 a mean of 5+2 mm Hg (P < 0.05) with 8 of 10 patients showing an increase (2-14 mm Hg). The alveolar-arterial oxygen difference, (A-a) Po2, widened in all correctors from a mean of 29±1 to 36±2 mm Hg (P < 0.01). The hematocrits decreased significantly from 54+2 to 48±2 (P < 0.02). In contrast, the noncorrectors showed no significant change in acid base status, Pao2, or hematocrit after MPA, although two patients lowered Paco2 3 mm Hg.
MPA) and(I the
Responses of ventilatory indices and timing to MPA are shown in Table II (mean values) and Fig. 2 (individual values). In the correctors, minute ventilation to CO2 production ratio (VE/VCo2) increased 15±4% (P < 0.01), with no significant change in CO2 production. The tidal volume increased significantly, a mean of 11±4% (P < 0.02) with 8 inspiratory effort (P0.l, dp/dt max, and VT/T1) were increased 11-14% (P < 0.05).
Lung volumes, airway resistance, and DLCOSB did not change. Oxygen consumption and respiratory exchange ratio did not change. Most patients increased oral temperatures after MPA (-0.02-+0.60C), but the mean change (36.8+0.2°C) was not statistically significant (P > 0.05).
In the noncorrectors, mean minute ventilation increased 18±8% with five of seven patients showing a ventilatory response (P > 0.05). However, the minute ventilation to CO2 production ratio increased only 9±6% (P > 0.05) (Fig. 2 and Table II ). Paco2 showed no significant change (0--3 mm Hg) (P > 0.1). The noncorrectors (n = 7) were divided into three groups based on response to MPA. First, no increase in minute ventilation was noted after MPA in two patients (R.S. and D.B.). Second, increased minute ventilation was associated with a 25 and 31% increase in Vco2 with no change in Paco2 in two patients (C.S. and M.P.). Third, increased minute ventilation and increased VE/VCO2 was achieved by increasing frequency rather than tidal volume in three patients (S.M., J.H., and R.K.). Consequently, Paco2 decreased only 7% despite a 13% increase in VE/VCO2. The functional residual capacity increased in five of seven noncorrectors (range, 5-20%). Otherwise, lung volumes, airway resistance, and DLCOSB did not change.
The effect of NIPA on resting Paco2 in the correctors was similar whether the patients were breathing air at a mean Pao2 of 52 min Hg (A Paco2 = -8± 1 mm Hg) or during acute correction of hypoxemia with 50% oxygen at a mean Pao2 of 169 mm Hg (A Paco2 = -9+ 1mm Hg) (Table IV) . Similarly, the acute depressant effects of hyperoxia on ventilation and ventilatory effort were similar before (A Paco2 = 4+1 mm Hg) and after (A Paco2 = 3+1 mm Hg) CO2 correction via MPA therapy. Noncorrectors showed no difference in the response to hyperoxia before or after MIPA therapy.
Lumbar CSF acid-base status was measure(d in six of ten correctors (Table I ). Pco2, [H+] , and( [HCO3] decreased significantly in CSF, and these changes were similar to those in arterial blood.
Assay of MPA related materials in plasma was 59+9 ng/ml in the correctors compared to 54±8 ng/ml in the noncorrectors (P > 0.2). CSF levels increasedl to 4.8+0.5 ng/ml duiring treatmiienit, which was 8% of the increase observed in plasmiia. In the two obese nloIncorrectors, MPA dose was raised from 60 to 110 Imig daily, producing a meani plasmia level of 68 ng/ml with no decrease in Paco2 compared to placebo.
The responses to VHV and exogenous CO2 were We measured several other factors that did not predict responsiveness to MPA therapy. These included resting pulmonary function tests, initial (control) acid-base status or degree of hypoxemia, and the acute response to either intravenous doxapram hydrochloride or exogenous CO2 measured in terms-of VE, dp/dtmax, VT, or f. Further, in a related study using the same patients, we found little correlation between the chronic ventilatory response to normalization of plasma [HCO3] via acetazalamide and that to MPA (22) .
Determinants ofchronic CO2 retention. The mechanism of chronic CO2 retention in patients with COPD remains controversial. The retention of CO2 is not closely correlated with the degree of airway obstruction. Alternatively, CO2 retention has been attributed to either subnormal ventilatory drive or "chemosensitivity" (23) (24) (25) (26) or to abnormalities in respiratory cycle timing (13) . We have attempted to identify the relative contributions of these factors to CO2 retention in our patient population by analysis of both the control data obtained in stable CO2 retention and the interpatient differences observed in response to chronic ventilatory stimulation via MPA.
The characteristics of our patients with COPD and CO2 retention were similar to those previously described (13, (27) (28) (29) . High indices of mechanical load and abnormal ventilation-perfusion relationships were manifested by a high A-ao2 difference and increased physiologic dead space. Augmented inspiratory effort in the face of increased mechanical load was documented by high Po., and normal mean inspiratory flow and minute ventilation relative to CO2 production, i.e., normal VEIVCO2. A rapid, shallow pattern of breathing with an abnormally shortened inspiratory duration was ineffective in maintaining alveolar ventilation despite normal VEIVCO2. We observed that whereas most patients increased inspiratory effort and VEIVCO2 with MPA therapy, their chronic CO2 retention was corrected only when tidal volume was also increased and was not corrected when a further increase in breathing frequency contributed most to the increased minute ventilation. These findings are consistent with the view from previous studies of patients with and without CO2 retention that respiratory cycle timing, specifically a reduced TX, contributes to chronic CO2 retention and its removal (13) .
On the other hand, it does not follow that a shortened inspiratory time, per se, will inevitably lead to CO2 retention and that inspiratory effort or drive is inconsequential as a determinant of CO2 retention or its correction. On the contrary, our prospective, longitudinal study showed that most patients on MPA therapy did not correct their original abnormality in respiratory cycle timing, (i.e., shortened T1, high frequency, and high dead space volume (VD/VT), and yet were able to correct their CO2 retention by increasing their inspiratory effort and thereby normalizing tidal volume. Similarly, Bradley, et al. (30) noted that a shortened inspiratory time was not necessarily associated with hypercapnia in hypoxemic patients with COPD. These findings demonstrate that although neuromuscular inspiratory effort is high in chronic CO2 retention, it is inadequate in the presence of mechanical and ventilation-perfusion abnormnalities to normalize arterial blood gases. A normocapnic state was produced in these patients only if chronic MPA therapy caused supernormal inspiratory effort, supern1ormal VE/Vco2 and normalization of tidal volume.
